<DOC>
	<DOCNO>NCT02909569</DOCNO>
	<brief_summary>This study evaluate effect twice daily dose INCB39110 treatment itch adult .</brief_summary>
	<brief_title>Relieving Chronic Itch : Oral Medication</brief_title>
	<detailed_description>Chronic idiopathic itch accompany low-grade skin inflammation . These inflammatory feature associate cytokine production signal common JAK1-STAT pathway . It therefore theorize selective JAK1 inhibitor INCB039110 may provide relief itch symptom .</detailed_description>
	<criteria>Male nonpregnant , nonlactating female subject age 18 year old Diagnosed chronic idiopathic pruritus ( CIP ) NRS Itch Score ≥ 7 Screening Baseline Diagnosis CIP least 6 week prior screen Willingness avoid pregnancy father child Ability willingness provide write informed consent Willing able comply study requirement restriction Willing participate interventional trial duration participation Subjects must good health determine medical history , physical examination , electrocardiogram , clinical laboratory test vital sign Failure course 2week course treatment topical triamcinolone 0.1 % ointment BID Histopathological demonstration skin dermal edema , eosinophil , mast cell activation lymphocytic infiltration 1 . Chronic pruritus due define primary dermatologic disorder ( e.g. , atopic dermatitis , psoriasis , etc . ) 2 . Patients prior diagnosis excoriation disorder 3 . Use topical treatment CIP ( bland emollient ) within 1 week baseline 4 . Systemic immunosuppressive immunomodulating drug ( eg , oral injectable corticosteroid , methotrexate , cyclosporine , mycophenolat mofetil , azathioprine ) within 4 week baseline 5 . Subjects cytopenias screening , define : 1 . Leukocytes &lt; 3 × 109/L 2 . Neutrophils &lt; low limit normal 3 . Lymphocytes &lt; 0.8 × 109/L 4 . Hemoglobin &lt; 10 g/dL 5 . Platelets &lt; 100 × 109/L 6 . Unwilling unable follow medication restriction unwilling unable sufficiently washout use restrict medication 7 . Use prohibit medication ( see Section 5.8 ) within 14 day 5 halflives ( whichever longer ) baseline visit 8 . Current clinically significant cardiovascular , respiratory , neurologic , hepatic , hematopoietic , renal gastrointestinal , endocrine metabolic dysfunction unless currently control stable , include ( limit ) follow : 1 . Positive hepatitis C antibody test ( antiHCAbF ) detectable RNA 2 . Positive hepatitis B surface antigen ( HBsAg ) hepatitis B core antibody ( HBcAb ) ; 3 . Positive HIV ( DUO test , p24 antigen ) 9 . Active malignancy 10 . Subjects history malignancy , except follow adequately treat , nonmetastatic malignancy : basal cell skin cancer , squamous cell carcinoma skin , situ cervical cancer 11 . History ( include family history ) current evidence congenital long QT syndrome know acquire QT prolongation 12 . Exposure investigational medication , include placebo , within 60 day Baseline Visit 13 . History intolerance and/or hypersensitivity medication similar INCB039110 ( e.g. , Xeljanz ) 14 . Participation previous INCB39110 trial 15 . Subjects severely impair liver function ( ChildPugh Class C ) endstage renal disease dialysis least 1 follow : 1 . Serum creatinine &gt; 1.5 mg/dL ; 2 . Alanine aminotransferase aspartate aminotransferase ≥ 1.5 × upper limit normal 16 . Anyone affiliate site sponsor and/or anyone may consent duress 17 . Any sound medical reason determine Investigator include condition may lead unfavorable riskbenefit study participation , may interfere study compliance may confound study result 18 . Subjects take potent systemic CYP3A4 inhibitor fluconazole within 2 week 5 halflives , whichever longer , baseline visit 19 . Subjects previously receive JAK inhibitor , systemic topical ( e.g . ruxolitinib , tofacitinib , baricitinib , filgotinib , lestaurtinib pacritinib ) 20 . Women pregnant breastfeed within 4 month screen . 21 . Current recent history ( &lt; 30 day screen and/or &lt; 45 day randomization ) clinically meaningful bacterial , fungal , parasitic , mycobacterial infection 22 . Clinically significant uncontrolled cardiac disease , include unstable angina , acute myocardial infarction within 6 month Day 1 study drug administration , New York Heart Association Class III IV congestive heart failure , arrhythmia require therapy uncontrolled hypertension ( blood pressure &gt; 150/90 mmHg ) unless approve medical monitor/sponsor 23 . History alcoholism drug addiction within 1 year screening , current alcohol drug use , opinion investigator , interfere subject 's ability comply administration schedule study assessment 24 . Subjects receive systemic chemotherapy time 25 . Subjects anticipate receive live liveattenuated vaccination screen final followup visit 26 . Subjects , opinion investigator , unable unlikely comply administration schedule study evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>